Monoclonal Antibody to Crystallin Beta B2 (CRYbB2)
| Code | Size | Price |
|---|
| MAF346Ra21-20ul | 20ul | £95.00 |
Quantity:
| MAF346Ra21-100ul | 100ul | £180.00 |
Quantity:
| MAF346Ra21-200ul | 200ul | £245.00 |
Quantity:
| MAF346Ra21-1ml | 1ml | £566.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Target Species: Rat
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
CCA2; CRYB2; CRYB2A; Beta-crystallin Bp
Buffer Formulation:
PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Item Name:
Crystallin Beta B2
Potency (Clone Number):
1:810000 (6#)
Reactivity:
Hu;Mu;
Source:
Monoclonal antibody preparation
Usage:
Western blotting: 0.5-5ug/ml<br/>Immunocytochemistry in formalin fixed cells: 5-30ug/ml<br/>Immunohistochemistry in formalin fixed frozen section: 5-30ug/ml<br/>Immunohistochemistry in paraffin section: 5-30ug/ml<br/>Enzyme-linked Immunosorbent Assay: 0.05-2ug/ml<br/>Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Crystallin Beta B2 (CRYbB2) | RPF346Ra01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||